Directory of funded grants

Filter by

556 results found

Modeling ALS progression by applying neuroinformatics to a novel in vitro human 3D tri-culture model of the disease

  • Program Type

    Team grants

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2023

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the motor neurons degenerate, leading to symptoms of muscle weakness and progressive paralysis, resulting in the death of patients from respiratory failure. The development of disease modifying therapies have been largely unsuccessful due to the poor understanding into the mechanisms…

Project Ongoing

See the project and researchers

DNA damage driven motor disturbance in ALS: An ERVK integrase transgenic mouse model

  • Program Type

    Team grants

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Manitoba

  • Start Date

    2023

  • Total Grant Amount

    $124,900

  • Health Canada Contribution

    $62,450

Project Overview

Endogenous retrovirus-K (ERVK) is a genomic viral symbiont that contributes towards ALS neuropathology. Our collaboration proposes to examine how ERVK integrase (IN) enzyme activity drives DNA damage, TDP-43 deregulation and neuronal loss, leading to motor disturbances using a novel ERVK IN transgenic mouse model system. The intent of this proposal…

Project Ongoing

See the project and researchers

Remote ischemic preconditioning treatment in amyotrophic lateral sclerosis

  • Program Type

    Team grants

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Alberta

  • Start Date

    2023

  • Total Grant Amount

    $124,000

  • Health Canada Contribution

    $62,000

Project Overview

RATIONALE: There are no effective disease modifying therapies for amyotrophic lateral sclerosis (ALS). Complete understanding of the physiopathology of ALS is lacking, and single-target therapies have failed clinical translation. The overarching goal of this grant application is to test the hypothesis that remote ischemic preconditioning (REIP), a non-invasive, endogenous, pleiotropic…

Project Ongoing

See the project and researchers

Deepening our understanding of G3BP1 and its paralog G3BP2 to facilitate accurate therapeutic development for ALS/FTD

  • Program Type

    Team grants

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2023

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

While significant efforts have been made worldwide, the development of an effective therapy to significantly slow or halt ALS disease progression has remained elusive. This is due in part to our incomplete understanding of the molecular mechanisms and aberrant processes that lead to disease. TDP-43 (TAR DNA binding protein 43)…

Project Ongoing

See the project and researchers

The impact of ALS disease variants on regulation of heat shock protein life cycles – Implications for neuronal proteostasis

  • Program Type

    Team grants

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2023

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

The abnormal accumulation of misfolded proteins and aggregates is the hallmark of multiple forms of ALS and other neurodegenerative diseases. The toxicity of these aberrant proteins is compounded by deficiency in mechanisms regulating protein quality control and alterations they cause in the metabolism of mRNAs that sustain neuronal functionality. A…

Project Ongoing

See the project and researchers